Alzheimer-kór: vizsgálatok itt: Puerto Rico

In Puerto Rico 9 Also abroad 815

9 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.

3. fázisTaking people
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Where
San Juan
Életkor
55 év to 90 év
People
426 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07011745 · EU 2025-520612-34-00
3. fázisTaking people
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Where
Bayamón
Életkor
55 év and over
People
550 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07602582
3. fázisTaking people
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
Where
Bayamón, San Juan
Életkor
55 év to 90 év
People
406 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Where
San Juan
Életkor
60 év to 85 év
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976216 · EU 2025-520746-30-00
3. fázisTaking people
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Where
San Juan
Életkor
50 év to 90 év
People
80 000 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07177352
3. fázisTaking people
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Where
Bayamón, Carolina, San Juan
Életkor
55 év to 90 év
People
1000 worldwide
Run by
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Where
Bayamón
Életkor
60 év to 85 év
People
586 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06976203 · EU 2025-520747-32-00
2/3. fázisTaking people
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
San Juan
Életkor
18 év and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT05552157
2/3. fázisTaking people
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Where
San Juan
Életkor
18 év and over
People
280 worldwide
Run by
Washington University School of Medicine
See details and how to joinNCT06647498